Nothing Special   »   [go: up one dir, main page]

BR0014414A - Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo - Google Patents

Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo

Info

Publication number
BR0014414A
BR0014414A BR0014414-2A BR0014414A BR0014414A BR 0014414 A BR0014414 A BR 0014414A BR 0014414 A BR0014414 A BR 0014414A BR 0014414 A BR0014414 A BR 0014414A
Authority
BR
Brazil
Prior art keywords
transformed
production
cell
transfected
thrombosis
Prior art date
Application number
BR0014414-2A
Other languages
English (en)
Inventor
Thomas Charles Boone
Huimin Li
Michael Benjamin Mann
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR0014414A publication Critical patent/BR0014414A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"POLIPEPTìDEO FIBRINOLITICAMENTE ATIVO, MOLéCULA DE áCIDO NUCLéICO, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, CéLULA PROCARIóTICA TRANSFORMADA OU TRANSFECTADA, CéLULA DE LEVEDURA TRANSFORMADA OU TRANSFECTADA, MéTODOS PARA A PRODUçãO DE NAT, PARA A PRODUçãO DE UM AGENTE FIBRINOLìTICO DE METALOPROTEINASE, E PARA O TRATAMENTO DE TROMBOSE EM UM MAMìFERO, E, ANTICORPO". Um polipeptídeo de metaloproteinase fibrinoliticamente ativo (chamado "trombolítico de ação nova") que é útil para a lise de coagulação do sangue in vivo e métodos e materiais para a sua produção pela expressão recombinante são descritos.
BR0014414-2A 1999-10-01 2000-09-29 Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo BR0014414A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/411,329 US6261820B1 (en) 1999-10-01 1999-10-01 Fibronolytically active polypeptide
PCT/US2000/027029 WO2001025445A1 (en) 1999-10-01 2000-09-29 Fibrinolytically active polypeptide

Publications (1)

Publication Number Publication Date
BR0014414A true BR0014414A (pt) 2002-06-11

Family

ID=23628486

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014414-2A BR0014414A (pt) 1999-10-01 2000-09-29 Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo

Country Status (29)

Country Link
US (4) US6261820B1 (pt)
EP (2) EP1224298B1 (pt)
JP (1) JP2003511034A (pt)
KR (2) KR100700753B1 (pt)
CN (2) CN101230340A (pt)
AT (1) ATE292180T1 (pt)
AU (1) AU767827B2 (pt)
BG (1) BG106577A (pt)
BR (1) BR0014414A (pt)
CA (1) CA2386185A1 (pt)
CZ (1) CZ298502B6 (pt)
DE (1) DE60019147T2 (pt)
DK (1) DK1224298T3 (pt)
EA (2) EA006487B1 (pt)
ES (1) ES2240167T3 (pt)
HK (1) HK1049351B (pt)
HU (1) HUP0202650A3 (pt)
IL (1) IL148787A0 (pt)
MX (1) MXPA02003126A (pt)
NO (1) NO20021501L (pt)
NZ (1) NZ517951A (pt)
PL (1) PL355017A1 (pt)
PT (1) PT1224298E (pt)
RS (1) RS20060033A (pt)
SG (1) SG127720A1 (pt)
SK (1) SK4232002A3 (pt)
WO (1) WO2001025445A1 (pt)
YU (2) YU59604A (pt)
ZA (1) ZA200202206B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US6523647B2 (en) * 2001-05-21 2003-02-25 Hydro Mobile Inc. Elevating platform assembly
CA2475761C (en) * 2002-02-11 2011-07-12 Gold-T Tech, Inc. An implantable device which provides high frequency ultrasound energy to provide acoustical streaming to prevent thrombus formation
US7016409B2 (en) * 2003-11-12 2006-03-21 Sony Corporation Apparatus and method for use in providing dynamic bit rate encoding
ES2239532B1 (es) * 2004-02-06 2006-11-01 Proyecto De Biomedicina Cima S.L. Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
US20070141625A1 (en) * 2005-02-03 2007-06-21 Santos Jose H Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
WO2007092820A2 (en) 2006-02-03 2007-08-16 Lazarus Effect, Inc. Methods and devices for restoring blood flow within blocked vasculature
EP2403583B1 (en) 2009-03-06 2016-10-19 Lazarus Effect, Inc. Retrieval systems
WO2011056872A2 (en) 2009-11-03 2011-05-12 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
WO2012129363A2 (en) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
WO2016040476A1 (en) 2014-09-09 2016-03-17 The Broad Institute, Inc. A droplet-based method and apparatus for composite single-cell nucleic acid analysis
US10456560B2 (en) 2015-02-11 2019-10-29 Covidien Lp Expandable tip medical devices and methods
WO2016145409A1 (en) 2015-03-11 2016-09-15 The Broad Institute, Inc. Genotype and phenotype coupling
US11092607B2 (en) 2015-10-28 2021-08-17 The Board Institute, Inc. Multiplex analysis of single cell constituents
WO2017075297A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. High-throughput dynamic reagent delivery system
EP3402902B1 (en) 2016-01-15 2021-10-27 Massachusetts Institute Of Technology Semi-permeable arrays for analyzing biological systems and methods of using same
US11072816B2 (en) 2017-05-03 2021-07-27 The Broad Institute, Inc. Single-cell proteomic assay using aptamers

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) * 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
US4447236A (en) * 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
DE3330699A1 (de) * 1983-08-25 1985-03-07 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) * 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) * 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
DK0438200T3 (da) * 1990-01-16 2002-11-11 Ct Ingenieria Genetica Biotech Fremgangsmåde til ekspression af heterologe gener i gæren Pichia pastoris, ekspressionsvektorer og transformerede mikroorganismer
US5709676A (en) * 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) * 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) * 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
ATE249234T1 (de) 1993-12-17 2003-09-15 Mochida Pharm Co Ltd Lösliches thrombomodulin enthaltende zubereitung
US5626564A (en) * 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US5830468A (en) 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
CA2255891C (en) * 1996-05-24 2007-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US5951981A (en) * 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) * 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
WO1999029838A1 (en) * 1997-12-09 1999-06-17 Bristol-Myers Squibb Company Fibrinogen-converting enzyme hybrids
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
AU2001281081A1 (en) 2000-08-03 2002-02-18 Zymogenetics Inc. Disintegrin homologs, zsnk10, zsnk11, and zsnk12

Also Published As

Publication number Publication date
ES2240167T3 (es) 2005-10-16
EP1605049A3 (en) 2006-12-13
MXPA02003126A (es) 2002-09-30
SG127720A1 (en) 2006-12-29
DE60019147D1 (en) 2005-05-04
WO2001025445A1 (en) 2001-04-12
HK1049351B (zh) 2005-07-29
EP1224298A1 (en) 2002-07-24
CN101230340A (zh) 2008-07-30
YU59604A (sh) 2005-11-28
NZ517951A (en) 2004-02-27
NO20021501L (no) 2002-05-31
DE60019147T2 (de) 2006-05-11
PT1224298E (pt) 2005-06-30
IL148787A0 (en) 2002-09-12
EP1224298B1 (en) 2005-03-30
US20020058322A1 (en) 2002-05-16
YU22502A (sh) 2005-07-19
US20080058256A1 (en) 2008-03-06
ZA200202206B (en) 2002-12-24
AU7625400A (en) 2001-05-10
US6617145B2 (en) 2003-09-09
JP2003511034A (ja) 2003-03-25
ATE292180T1 (de) 2005-04-15
PL355017A1 (en) 2004-03-22
KR100700753B1 (ko) 2007-03-28
US7195903B2 (en) 2007-03-27
NO20021501D0 (no) 2002-03-26
DK1224298T3 (da) 2005-05-30
BG106577A (bg) 2003-04-30
US6261820B1 (en) 2001-07-17
CZ20021034A3 (cs) 2003-06-18
EA200400290A1 (ru) 2005-02-24
US20030186422A1 (en) 2003-10-02
CZ298502B6 (cs) 2007-10-24
KR100711312B1 (ko) 2007-04-27
EP1605049A2 (en) 2005-12-14
CA2386185A1 (en) 2001-04-12
HUP0202650A3 (en) 2005-01-28
KR20020047208A (ko) 2002-06-21
HUP0202650A2 (hu) 2002-12-28
AU767827B2 (en) 2003-11-27
SK4232002A3 (en) 2003-09-11
EA005944B1 (ru) 2005-08-25
RS20060033A (sr) 2006-12-15
KR20060114034A (ko) 2006-11-03
HK1049351A1 (en) 2003-05-09
CN100357430C (zh) 2007-12-26
CN1402788A (zh) 2003-03-12
EA006487B1 (ru) 2005-12-29
EA200200410A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
BR0014414A (pt) Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo
FI911049A0 (fi) Vaevnadsplasminogenaktivator med zymogena eller fibrinspecifika egenskaper.
JP2003511034A5 (pt)
FI854395A0 (fi) Sv40-expressionsvektor innehaollande hbxag-antigen som expressionsmarkering.
Louw et al. Action of thyrocalcitonin in the teleost fish Ictalurus melas
FR2812303B1 (fr) Procede de lyse cellulaire de procaryotes ou d'eucaryotes ou de lyse cellulaire simultanee de procaryotes et d'eucaryotes
Machovich et al. Denatured proteins as cofactors for plasminogen activation
Okada et al. Analysis of plasminogen activation by the plasmin–staphylokinase complex in plasma of α2-antiplasmin-deficient mice
ATE93273T1 (de) Neue fibrinolytische enzyme.
Johnsen et al. Kinetic and structural characterization of a two-domain streptokinase: dissection of domain functionality
Kolev et al. Dual effect of synthetic plasmin substrates on plasminogen activation
ES2061719T3 (es) Proceso para la produccion de proteinas.
Lopez-Sendon et al. Cardiovascular pharmacology (XIII). The efficacy of different thrombolytic drugs in the treatment of acute myocardial infarct
Hernández et al. Determination of streptokinase activity by quantitative assay.
Avilan et al. Cloning, expression and purification of recombinant streptokinase: partial characterization of the protein expressed in Escherichia coli
Collen Fibrin-specific thrombolytic agents.
Dewerchin et al. Characterisation of conjugates of thrombin-treated single chain urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin
Rafipour et al. Evaluation of the α2-Antipalsmin-Resistance of a Domain Exchanged-Chimeric Streptokinase from Two Streptococci Groups
Carranza et al. Effect of oversulfated chondroitin-6-sulfate or oversulfated fucoidan in the activation of glutamic plasminogen by tissue plasminogen activator: role of lysine and cyanogen bromide-fibrinogen
Aĭsina et al. Inactivation and stabilization of urokinase fibrinolytic activity in vitro
Ambrus et al. Mechanism of action of fibrinolytic enzymes in vivo.
Seifried The fibrinolytic system and its activators
Comp A rapid purification of streptokinase by affinity chromatography
Van de Werf Coronary patency after thrombolysis.
Lijnen Mechanism of action and thrombolytic potential of staphylokinase.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: O DEPOSITANTE DEVERA APRESENTAR A PETICAO DEVIDA PARA O CUMPRIMENTO DESTA EXIGENCIA EM ATE 60 (SESSENTA) DIAS, CONTADOS A PARTIR DA DATA DE PUBLICACAO NA RPI, DE ACORDO COM O ART. 34 (II) DA LPI PARA QUE SE DE INICIO AO EXAME TECNICO DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]